IRON · Program file
bitopertin
When did Disc Medicine, Inc. say bitopertin results would come?
On , Disc Medicine, Inc. wrote in its SEC Form 10-Q: “We completed enrollment in APOLLO (n=183) in the first quarter of 2026 and expect to report topline data in the fourth quarter of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “fourth quarter of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- bitopertin
- Other names in filings
- APOLLO
- Indication in the filing
- erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)
- Trials named in the same filing
- None listed
- Latest timing wording
- “We completed enrollment in APOLLO (n=183) in the first quarter of 2026 and expect to report topline data in the fourth quarter of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-325034 · SEC original
- Last checked
Program IRON-bitopertin.